Skip to main content
Contact Us
Subscribe
E-Edition
42°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Haemonetics Corp
(NY:
HAE
)
85.43
+0.51 (+0.60%)
Official Closing Price
Updated: 7:00 PM EST, Nov 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Haemonetics Corp
< Previous
1
2
3
4
5
Next >
4 Analysts Have This to Say About Haemonetics
August 09, 2023
Via
Benzinga
Haemonetics Earnings Preview
August 07, 2023
Via
Benzinga
Haemonetics Corp. (NYSE: HAE) Making Surprising Moves in Monday Session
July 17, 2023
Via
Investor Brand Network
Haemonetics Q4 Earnings Exceed Expectations On Volume And Price Benefits
May 11, 2023
Via
Benzinga
Recap: Haemonetics Q4 Earnings
May 11, 2023
Via
Benzinga
Looking Into Haemonetics's Return On Capital Employed
February 08, 2023
Via
Benzinga
Alphabet To Rally Over 20%? Here Are 10 Other Analyst Forecasts For Wednesday
February 08, 2023
Loop Capital boosted the price target for Alphabet Inc. (NASDAQ: GOOGL) from $120 to $125. Loop Capital analyst Rob Sanderson maintained a Buy rating. Alphabet shares fell 3.7% to $103.70 in pre-market...
Via
Benzinga
Earnings Preview: Haemonetics
February 06, 2023
Via
Benzinga
Where Haemonetics Stands With Analysts
January 24, 2023
Via
Benzinga
9 Analysts Have This to Say About Haemonetics
December 12, 2022
Via
Benzinga
Watch for Continued Gains in Shares of Haemonetics Corporation (HAE)
September 12, 2022
Via
Investor Brand Network
Incyte, Haemonetics Post Earnings Beats; One Surges Within Buy Zone
February 07, 2023
Haemonetics stock rose within a buy zone on Tuesday, but Incyte stock toppled.
Via
Investor's Business Daily
How 2022's Biggest Healthcare Gainers Could Fare In 2023
January 06, 2023
Health care stocks were hit hard early in the pandemic but these three have made quite a comeback. This article examines where they could go in 2023
Via
MarketBeat
InMode Stock Shows Improved Technical Strength; Hits Key Technical Threshold
November 16, 2022
The Relative Strength (RS) Rating for InMode stock moved up into a higher percentile Wednesday, as it got a lift from 64 to 78.
Via
Investor's Business Daily
Analysts Take Bullish Stance On Haemonetics, Cites Plasma Momentum As Catalyst
November 08, 2022
Via
Benzinga
Haemonetics: Q2 Earnings Insights
November 07, 2022
Haemonetics (NYSE:HAE) reported its Q2 earnings results on Monday, November 7, 2022 at 06:00 AM. Here's what investors need to know about the announcement. Earnings Haemonetics beat estimated earnings...
Via
Benzinga
Expert Ratings for Haemonetics
October 13, 2022
Over the past 3 months, 6 analysts have published their opinion on Haemonetics (NYSE:HAE) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...
Via
Benzinga
Where Haemonetics Stands With Analysts
August 11, 2022
Within the last quarter, Haemonetics (NYSE:HAE) has observed the following analyst ratings:
Via
Benzinga
Haemonetics: Q1 Earnings Insights
August 10, 2022
Haemonetics (NYSE:HAE) reported its Q1 earnings results on Wednesday, August 10, 2022 at 06:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Haemonetics Stock Near Buy Zone With EPS Due
July 27, 2022
With its next earnings report scheduled for around Aug. 10, Haemonetics stock is trading about 10% shy of a 75.44 buy point.
Via
Investor's Business Daily
Stocks That Hit 52-Week Lows On Thursday
December 01, 2022
During Thursday's session, 108 stocks hit new 52-week highs.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2022
October 13, 2022
Upgrades
Via
Benzinga
Raymond James Thinks Haemonetics Growth Is 'Underappreciated'
July 01, 2022
Via
Benzinga
Leading Medical Stocks, Including Sensus And Shockwave, Have Grown At Least 36% This Year
October 05, 2022
Biotech isn't the only place to make money in health care this year.
Via
Investor's Business Daily
Cutera Stock Earns Relative Strength Rating Upgrade
October 03, 2022
On Monday, medical aesthetic Cutera stock had its Relative Strength (RS) Rating upgraded to 90 from 80 a day earlier.
Via
Investor's Business Daily
Important Biotech Catalysts For September 12, 2022 - End Of The Day Summary
September 12, 2022
Via
Benzinga
Stock Market Rally Rises On Inflation Data; Nvidia, Micron, Tesla, Disney In Focus: Weekly Review
August 12, 2022
The major indexes continued to advance, despite some key warnings.
Via
Investor's Business Daily
Haemonetics Surges Closer To A Breakout After Squashing Quarterly Estimates, Raising Guidance
August 10, 2022
The blood and plasma supplies provider also raised its sales guidance for the fiscal year.
Via
Investor's Business Daily
InMode Stock Scores Relative Strength Rating Upgrade; Hits Key Threshold
August 09, 2022
On Tuesday, InMode stock got a positive adjustment to its Relative Strength (RS) Rating, to 86 from 72 a day earlier.
Via
Investor's Business Daily
ShockWave Medical Stock Scores Rising Price Performance With Jump To 92 RS Rating
July 11, 2022
ShockWave Medical stock saw a welcome improvement to its Relative Strength (RS) Rating on Monday, with an increase from 81 to 92.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.